HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Birth Control Not Good For Women's Health, Natural Family Planning Group Says

Executive Summary

SymptoPro Fertility Education focuses comments to FDA on potential side effects from Opill, suggesting its use could be linked to increased breast cancer risk, depression and ectopic pregnancy. Guttmacher Institute supports approval, saying “adolescents have most to gain.”

You may also be interested in...

Catholic Group Asserts Alarm About Teen Access Among Doubts About Safety Of OTC Birth Control

In comment among dozens posted at deadline shortly before FDA advisory panel meeting in May on HRA Pharma’s Opill proposal, Pro-Family Women says, “American women’s typical use of contraceptives, when put into real-world practice, often do not prevent pregnancy.” Other advocacy and professional groups’ comments near deadline urge approval to expand access.

Another State Approves Pharmacy Access To Hormonal Contraceptives

Indiana allows pharmacists, through a standing order from state health agency, to prescribe some hormonal contraceptives in pill or patch form. American College of Obstetricians and Gynecologists among recent supporters of OTC approval in comments to FDA.

Federal Ban On PFAs In Cosmetics Could Ensure National Uniformity; It Also Could Drive Litigation

While studies are limited regarding the human health effects of PFAS in cosmetic products, efforts to prohibit their use continue gaining steam at the state and federal levels, which could lead to increased litigation.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts